MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Neuronetics Market Cap 2011-2025 | STIM
As of December 15, 2025 Neuronetics has a market cap of $ 46.3 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Neuronetics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 121 M | 85.1 M | 293 M | 71.3 M | 151 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 293 M | 71.3 M | 144 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Diagnostics research industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
221 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
75.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
240 M | $ 16.71 | -0.83 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
2.95 B | $ 16.22 | 2.97 % | $ 175 M |  China |
 |
Accelerate Diagnostics
AXDX
|
40.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
5.93 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
3.55 M | $ 1.57 | -3.4 % | $ 2 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
421 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
709 M | $ 38.53 | -0.26 % | $ 1.07 B | USA |
 |
DarioHealth Corp.
DRIO
|
43.4 M | $ 11.99 | 0.84 % | $ 340 M | Israel |
 |
Chembio Diagnostics
CEMI
|
12.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
48.8 B | $ 66.15 | -1.22 % | $ 25.5 B | USA |
 |
Danaher Corporation
DHR
|
152 B | $ 226.11 | -0.17 % | $ 165 B | USA |
 |
Exact Sciences Corporation
EXAS
|
9.32 B | $ 101.52 | 0.01 % | $ 18.8 B | USA |
 |
Fulgent Genetics
FLGT
|
467 M | $ 26.92 | -0.81 % | $ 814 M | USA |
 |
Global Cord Blood Corporation
CO
|
243 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
481 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
9.22 B | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
1.54 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
42.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
7.87 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
521 M | $ 19.95 | -2.97 % | $ 1.07 B | USA |
 |
Celcuity
CELC
|
399 M | $ 101.73 | -3.34 % | $ 4.01 B | USA |
 |
Enzo Biochem
ENZ
|
57.5 K | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
70.8 K | $ 3.29 | -8.24 % | $ 105 K | USA |
 |
Co-Diagnostics
CODX
|
34.9 M | $ 0.31 | -9.7 % | $ 9.1 M | USA |
 |
IQVIA Holdings
IQV
|
35.7 B | $ 221.67 | -0.25 % | $ 40.2 B | USA |
 |
Guardant Health
GH
|
5.84 B | $ 103.94 | 1.83 % | $ 12.8 B | USA |
 |
Aspira Women's Health
AWH
|
45.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
844 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
2.99 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
16.4 B | $ 133.75 | -0.83 % | $ 21.3 B | USA |
 |
Charles River Laboratories International
CRL
|
8.54 B | $ 196.94 | 2.05 % | $ 10.1 B | USA |
 |
Quotient Limited
QTNT
|
183 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
19.1 B | $ 183.42 | 0.5 % | $ 20.4 B | USA |
|
Biodesix
BDSX
|
92.1 M | $ 7.63 | -2.8 % | $ 989 M | USA |
 |
Mettler-Toledo International
MTD
|
29.9 B | $ 1 405.95 | 0.86 % | $ 29.8 B | Schweiz |
 |
Myriad Genetics
MYGN
|
973 M | $ 6.96 | -3.47 % | $ 631 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
21.1 B | $ 261.21 | -1.12 % | $ 21.9 B | USA |
 |
ICON Public Limited Company
ICLR
|
16.6 B | $ 181.89 | -2.51 % | $ 15 B |  Irlanda |
 |
NeoGenomics
NEO
|
1.53 B | $ 11.99 | 1.14 % | $ 1.52 B | USA |
 |
Neogen Corporation
NEOG
|
1.02 B | $ 6.78 | -1.16 % | $ 1.47 B | USA |
 |
IDEXX Laboratories
IDXX
|
37.7 B | $ 698.37 | -0.83 % | $ 57.6 B | USA |
 |
Lantheus Holdings
LNTH
|
6.47 B | $ 67.15 | 0.79 % | $ 4.65 B | USA |
 |
Agilent Technologies
A
|
42 B | $ 139.73 | 0.05 % | $ 42.5 B | USA |
 |
Biomerica
BMRA
|
7.19 M | $ 2.43 | -4.8 % | $ 5.58 M | USA |
 |
Bioventus
BVS
|
351 M | $ 7.53 | -0.26 % | $ 472 M | USA |
 |
Check-Cap Ltd.
CHEK
|
4.33 M | - | - | $ 9.42 M | Israel |
 |
Motus GI Holdings
MOTS
|
990 K | - | -34.28 % | $ 263 K | Israel |
 |
Pacific Biosciences of California
PACB
|
1.41 B | $ 2.1 | -1.18 % | $ 533 M | USA |